Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

258.14
-4.7600-1.81%
Volume:1.68M
Turnover:433.96M
Market Cap:456.23B
PE:72.93
High:262.50
Open:262.50
Low:257.25
Close:262.90
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.49
T/O Rate:0.10%
Dividend:6.83
Dividend Rate:2.65%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-76.87
PE(LYR):109.38

Loading ...

AbbVie’s New Phase 1 ABBV-859 Trial: Early Pipeline Signal for Long-Term Investors

TIPRANKS
·
Jul 31

AbbVie’s ABBV-722 Clears Key Safety Hurdle in Contraceptive Interaction Study

TIPRANKS
·
Jul 31

Movement Alert|AbbVie Falls 3.15% in Regular Trading, Biotech Sector Selloff Compounds Pre-Earnings Pressure

Market Focus
·
Jul 30

July 2026's Top Stocks Believed To Be Trading Below Intrinsic Value

Simply Wall St.
·
Jul 29

AbbVie announces Elahere availability in Singapore

TIPRANKS
·
Jul 29

AbbVie announces European Commission approval for Rinvoq

TIPRANKS
·
Jul 29

AbbVie price target raised to $300 from $275 at Barclays

TIPRANKS
·
Jul 29

U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal

Reuters
·
Jul 29

AbbVie Says EU Approves Rinvoq for Non-segmental Vitiligo Treatment

Reuters
·
Jul 29

Abbvie Announces European Commission Approval of Rinvoq® (Upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

THOMSON REUTERS
·
Jul 29

Basilea Publishes Investor Presentation on Hospital Anti-infectives Portfolio and Pipeline

Reuters
·
Jul 29

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 29

AbbVie Inc Stock (ABBV) Moved Up by 3.35% on Jul 28: A Full Analysis

TradingKey
·
Jul 28

Movement Alert|AbbVie Rises 3.06% in Regular Trading, Barclays Raises Target Price to $300 Ahead of Q2 Earnings

Market Focus
·
Jul 28

Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating

MT Newswires Live
·
Jul 28

Analysts Are Bullish on These Healthcare Stocks: Opko Health (OPK), AbbVie (ABBV)

TIPRANKS
·
Jul 28

AbbVie Wraps Up Real-World RINVOQ Study in Psoriatic Arthritis: What Investors Should Watch

TIPRANKS
·
Jul 28

Sarepta Gains After Appointing Former AbbVie Executive Severino as CEO

Reuters
·
Jul 27

Sarepta Names Michael Severino CEO, Succeeding Retiring Doug Ingram

Reuters
·
Jul 27

AbbVie (ABBV) Misses Key Phase 3 Survival Goal For Epcoritamab In DLBCL

Simply Wall St.
·
Jul 25